TURKU, Finland, September 23, 2013 /PRNewswire/ --
ArcDia Ltd (http://www.arcdia.com). ArcDia International Ltd today announced the expansion of its distributor and service network to cover 18 countries in Europe and Middle-East, twelve of which have been signed during the last four months. mariPOC® is a rapid point-of-care diagnostic test to detect nine pathogens from one nasal swap sample in 20 minutes. mariPOC® respi test is designed for testing upper and lower respiratory tract infections. The test system allows rapid detection and differentiation between viral and bacterial infections.
"We started to work with mariPOC® already in early 2012. The mariPOC® diagnosticsplatform provides performance, cost-efficiency and usability needed in clinics. Fast resultsenable better patient care", says Mr. Ferran Prat, Director of Diagnostic unit at Laboratories LETI, distributor of mariPOC® in Spain and Portugal.
"mariPOC® immunodiagnostics performs in practice better than molecular diagnostics thatcan be too costly and complex to use. Market response has been extremely good, anddoctors, nurses and patients like the test better than taking multiple samples or waiting forone or two days for the results", says Jesper Floyd Kristiansen, VP Sales and Marketing at ArcDia Ltd.
About mariPOC®
mariPOC® provides multianalyte diagnostic results for influenza like illnesses and tonsillitis in near patient settings in 20 minutes. The mariPOC® applications are targeted to acute respiratory infections, the most common infectious diseases on Earth. mariPOC® is superior in performance to the conventional test methods, including lateral flow rapid tests and standard bacterial culture. mariPOC® is designed to improve patient management and quality of health care, and it allows timely pathogen-specific diagnostics and medication. For the complete list of distributors visit http://arcdia.com/eng/contact/distribution/
About ArcDia
ArcDia International Ltd is the manufacturer of mariPOC®, world's first multianalyte point-of care diagnostics test for respiratory tract infections. In the future, the company will develop additional point-of-care tests based on its proprietary ArcDia' TPX detection technology. (Nature Biotech 2000:18). The technology is available for prominent industrial parties for inlicensing. Currently, ArcDia is actively seeking distribution partners for mariPOC®. For more information visit http://www.arcdia.com
